Back to top
more

Twist Bioscience (TWST)

(Delayed Data from NSDQ)

$87.56 USD

87.56
3,938,555

+4.69 (5.66%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $87.48 -0.08 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.

Zacks Equity Research

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?

Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 5.95% and 6.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Sweta Killa headshot

5 Best Performing Stocks of the Top ETF of November

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 13.83% and 5.52%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 7.95% and 14.09%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 11.40% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?